45 results on '"Ruiz-Casado A"'
Search Results
2. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
- Author
-
M. Toledano-Fonseca, M.A. Gómez-España, E. Élez, C. Grávalos, P. García-Alfonso, R. Rodríguez, F. Losa, I. Alés Díaz, B. Graña, M. Valladares-Ayerbes, M.V. García-Ortiz, E. Polo, M. Salgado, F. Rivera, M.J. Safont, A. Salud, A. Ruiz-Casado, J.M. Tabernero, M.C. Riesco, A. Rodríguez-Ariza, and E. Aranda
- Subjects
Biomarkers ,Circulating miRNAs ,Colorectal cancer ,Aflibercept ,Antiangiogenic therapy ,Therapeutics. Pharmacology ,RM1-950 - Abstract
The benefit of adding the antiangiogenic drug aflibercept to FOLFIRI regime in metastatic colorectal cancer (CRC) patients resistant to or progressive on an oxaliplatin-based therapy has been previously demonstrated. However, the absence of validated biomarkers to predict greater outcomes is a major challenge encountered when using antiangiogenic therapies. In this study we investigated profiles of circulating microRNAs (miRNAs) to build predictive models of response to treatment and survival. Plasma was obtained from 98 metastatic CRC patients enrolled in a clinical phase II trial before receiving FOLFIRI plus aflibercept treatment, and the circulating levels of 754 individual miRNAs were quantified using real-time PCR. A distinct signature of circulating miRNAs differentiated responder from non-responder patients. Remarkably, most of these miRNAs were found to target genes that are involved in angiogenic processes. Accordingly, some of these miRNAs had predictive value and entered in predictive models of response to therapy, progression of disease, and survival of patients treated with FOLFIRI plus aflibercept. Among these miRNAs, circulating levels of hsa-miR-33b-5p efficiently discriminated between responder and non-responder patients and predicted the risk of disease progression. Moreover, the combination of circulating VEGF-A and miR-33b-5p levels improved clinical stratification of metastatic CRC patients who were to receive FOLFIRI plus aflibercept treatment. In conclusion, our study supports circulating miRNAs as valuable biomarkers for predicting better outcomes in metastatic CRC patients treated with FOLFIRI plus aflibercept.
- Published
- 2023
- Full Text
- View/download PDF
3. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
- Author
-
Vera, Ruth, Mata, Elena, González, Encarna, Juez, Ignacio, Alonso, Vicente, Iranzo, Patricia, Martínez, Nieves P., López, Carlos, Cabrera, José M., Safont, María J., Ruiz-Casado, Ana, Salgado, Mercedes, González, Beatriz, Escudero, Pilar, Rivera, Fernando, and Pericay, Carles
- Published
- 2020
- Full Text
- View/download PDF
4. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.
- Author
-
Español-Rego, Marta, Fernández-Martos, Carlos, Elez, Elena, Foguet, Carles, Pedrosa, Leire, Rodríguez, Nuria, Ruiz-Casado, Ana, Pineda, Estela, Cid, Joan, Cabezón, Raquel, Oliveres, Helena, Lozano, Miquel, Ginés, Angels, García-Criado, Angeles, Ayuso, Juan Ramon, Pagés, Mario, Cuatrecasas, Miriam, Torres, Ferràn, Thomson, Timothy, and Cascante, Marta
- Subjects
DENDRITIC cells ,COLORECTAL cancer ,METASTASIS ,CANCER patients ,CANCER vaccines ,HEREDITARY nonpolyposis colorectal cancer - Abstract
Background: Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic effects. Methods: This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor effects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efficacy of the combination. The primary end-point was 40% progression-free survival at 6 months with a 2 Simon Stage. Results: A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design first-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1–5.3 months] and overall survival was 12.2 months [3.2–23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted significant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, inflammation and oxidative stress pathways. Conclusions: The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the first-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapy-induced tumor vulnerabilities. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
- Author
-
Ignacio Juez, Ana Ruiz-Casado, Carles Pericay, Vicente Alonso, José M Cabrera, Maria Jose Safont, M. Salgado, Pilar Escudero, Ruth Vera, Fernando Rivera, Patricia Iranzo, E. González, Nieves P Martínez, Elena Mata, Carlos F. Lopez, and Beatriz González
- Subjects
Male ,medicine.medical_specialty ,Colorectal cancer ,Recombinant Fusion Proteins ,Perforation (oil well) ,Leucovorin ,Gastroenterology ,Disease-Free Survival ,Capecitabine ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Regorafenib ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Aflibercept ,business.industry ,Middle Aged ,Hepatology ,Prognosis ,medicine.disease ,Survival Analysis ,Primary tumor ,ErbB Receptors ,Receptors, Vascular Endothelial Growth Factor ,chemistry ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Toxicity ,ras Proteins ,Camptothecin ,Female ,030211 gastroenterology & hepatology ,Fluorouracil ,Colorectal Neoplasms ,business ,medicine.drug - Abstract
To determine the efficacy and safety data of aflibercept + FOLFIRI in wt RAS mCRC patients after progression to standard chemotherapy + anti-EGFR treatment. Retrospective, observational study in real life conducted in wt RAS mCRC patients treated with FOLFIRI-aflibercept after progression to standard first line chemotherapy + anti-EGFR treatment. A total of 120 patients from 12 Spanish hospitals were enrolled. Median age is 60 years (62.5%/37.5%male/female). Primary tumor site is 24.1%/75.9% right/left-side colon, and 40.8% of patients had a prior resection. All patients had wild-type RAS tumors including 5% of patients with BRAF mutations and received anti-EGFR treatment. At the time aflibercept was initiated, ECOG PS is 0/1 in 96% of patients. Median number of FOLFIRI-aflibercept cycles is 12. Efficacy results: Overall response rate is 33%; progression-free survival (PFS) is 6.9 months (95%CI: 6.1–7.8). Primary tumor resection was the only significant variable related to PFS in the multivariate analysis. Median overall survival (OS) is 14.5 months (95%CI: 9.7–19.3). ECOG and number of metastatic sites were related to OS in multivariate analysis. About 54.1% of patients received a third-line therapy including TAS-102 (23%), regorafenib (18.5%), and capecitabine (9.2%). Toxicity: Grade 3–4 toxicities were observed in 37.5% of the patients (hematologic 16.6%, hypertension 7.5%, asthenia 5.9%, and perforation 2.5%). Aflibercept dose was reduced in 18.3% of patients. The results show that patients with wt RAS mCRC who received an anti-EGFR as part of the first-line treatment achieved similar RR, PFS, OS, and toxicities to those reported in VELOUR trial. These results suggest that FOLFIRI-aflibercept after first-line treatment with anti-EGFR is an appropriated option for RAS wt mCRC.
- Published
- 2020
6. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
- Author
-
Elena Élez, María Auxiliadora Gómez-España, Cristina Grávalos, Pilar García-Alfonso, María José Ortiz-Morales, Ferrán Losa, Inmaculada Alés Díaz, Begoña Graña, Marta Toledano-Fonseca, Manuel Valladares-Ayerbes, Eduardo Polo, Mercedes Salgado, Eva Martínez de Castro, María José Safont, Antonieta Salud, Ana Ruiz-Casado, Josep Tabernero, María del Carmen Riesco, Antonio Rodriguez-Ariza, Enrique Aranda, Grupo de Tratamiento de los Tumores Digestivos, Sanofi, Tabernero, Josep, and Aranda, Enrique
- Subjects
Vascular Endothelial Growth Factor A ,Cancer Research ,Recombinant Fusion Proteins ,Leucovorin ,Irinotecan ,Colorectal cancer ,Article ,Combination drug therapy ,Receptors, Vascular Endothelial Growth Factor ,Oncology ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Camptothecin ,Fluorouracil ,Colorectal Neoplasms ,Biomarkers - Abstract
[Background] Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated. We assessed aflibercept plus FOLFIRI, investigating the biomarker role of baseline vascular endothelial growth factor A (VEGF-A) and angiotensin-converting enzyme (ACE)., [Methods] Phase II trial in oxaliplatin-treated mCRC patients who received aflibercept plus FOLFIRI. The reported 135 ng/mL ACE cut-off was used and ROC analysis was performed to assess the optimal VEGF-A cut-off for progression-free survival (PFS). Overall survival (OS), time to progression (TTP), time to treatment failure (TTF), overall response rate (ORR) and disease control rate (DCR) were also assessed., [Results] In total, 101 patients were followed for a median of 12 (6–17) months. The 1941 pg/mL VEGF-A was an optimal cut-off, with a longer median PFS when VEGF-A was, [Conclusions] This study supports aflibercept plus FOLFIRI benefits, suggesting VEGF-A as a potential biomarker to predict better outcomes., This work was supported by the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) through an unrestricted grant provided by Sanofi (no grant number is applicable).
- Published
- 2021
7. Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
- Author
-
García-Alfonso, Pilar, Muñoz, Andrés, Jiménez-Castro, Jerónimo, Jiménez-Fonseca, Paula, Pericay, Carles, Longo-Muñoz, Federico, Reyna-Fortes, Carmen, Argilés-Martínez, Guillem, González-Astorga, Beatriz, Gómez-Reina, María José, Ruiz-Casado, Ana, Rodríguez-Salas, Nuria, López-López, Rafael, Carmona-Bayonas, Alberto, Conde-Herrero, Verónica, Aranda, Enrique, On Behalf Of The Ros Study Group, ROS Study Group are listed in acknowledgments, [García-Alfonso,P, Muñoz,A] Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Jiménez-Castro,J] Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain. [Jiménez-Fonseca,P] Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain. [Pericay,C] Department of Medical Oncology, Hospital Universitari Parc Taulí, Sabadell, Spain. [Longo-Muñoz,F] Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Reyna-Fortes,C] Department of Medical Oncology, UGC Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain. [Argilés-Martínez,G] Department of Medical Oncology, Hospital Universitari Vall d’Hebrón, Barcelona, Spain. [González-Astorga,B] Department of Medical Oncology, Hospital Universitario Clínico San Cecilio, Granada, Spain. [Gómez-Reina,MJ] Department of Medical Oncology, Hospital Universitario Puerta del Mar, Cádiz, Spain. [Ruiz-Casado,A] Department of Medical Oncology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain. [Rodríguez-Salas,N] Department of Medical Oncology, Hospital Universitario La Paz, CIBERONC, Madrid, Spain. [López-López,R] Translational Medical Oncology Group, Department of Medical Oncology, Hospital Clínico Universitario e Instituto de Investigación Sanitaria (IDIS), CIBERONC, Facultad de Medicina de la Universidad de Santiago de Compostela, Santiago de Compostela, Spain. [Carmona-Bayonas,A] Department of Medical Oncology, Hospital General Universitario Morales Meseguer, Murcia, Spain. [Conde-Herrero,V] Department of Medical Oncology, Hospital Universitario Virgen de las Nieves, Granada, Spain. [Aranda,E] Department of Medical Oncology, Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, Spain., This work was supported by the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) through a grant provided by Laboratorios Servier S.L. (grant reference number: not applicable), Institut Català de la Salut, [García-Alfonso P, Muñoz A] Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Jiménez-Castro J] Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain. [Jiménez-Fonseca P] Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain. [Pericay C] Department of Medical Oncology, Hospital Universitari Parc Taulí, Sabadell, Spain. [Longo-Muñoz F] Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Argilés-Martínez G] Servei d’oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Oncology ,Cancer Research ,Diseases::Digestive System Diseases::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings] ,Colorectal cancer ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [Medical Subject Headings] ,medicine.medical_treatment ,Trifluridine ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,chemotherapy ,Metastasis ,combination therapy ,trifluridine/tipiracil ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Còlon - Càncer - Tractament ,chemistry.chemical_compound ,Neoplasias colorrectales ,Quimioterapia combinada ,RC254-282 ,Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Esterases::Phosphoric Monoester Hydrolases::Alkaline Phosphatase [Medical Subject Headings] ,terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Trifluridine/tipiracil ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Real-life ,Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Platelet Disorders::Thrombocytopenia [Medical Subject Headings] ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES] ,Trifluridina ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Anthropometry::Body Weights and Measures::Tumor Burden [Medical Subject Headings] ,Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropenia [Medical Subject Headings] ,Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia [Medical Subject Headings] ,medicine.drug ,medicine.medical_specialty ,Combination therapy ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,colorectal cancer ,Article ,Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES] ,Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines::Pyrimidine Nucleosides::Thymidine::Trifluridine [Medical Subject Headings] ,Refractory ,Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Internal medicine ,Recte - Càncer - Tractament ,medicine ,Chemotherapy ,Anatomy::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes [Medical Subject Headings] ,real-life ,Tipiracil ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings] ,Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms [Medical Subject Headings] ,Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Regression Analysis [Medical Subject Headings] ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression [Medical Subject Headings] ,business.industry ,Proportional hazards model ,diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,biomarkers ,Retrospective cohort study ,Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,medicine.disease ,Biomarcadores ,chemistry ,Avaluació de resultats (Assistència sanitària) ,Quimioterapia ,Anatomy::Cells::Blood Cells::Leukocytes::Granulocytes::Neutrophils [Medical Subject Headings] ,business ,Biomarkers - Abstract
Trifluridine/tipiracil is currently approved for metastatic colorectal cancer (mCRC) refractory to available therapies. However, there is no consensus on factors that predict treatment outcomes in daily practice. We assessed the early clinical experience with trifluridine/tipiracil in Spain and potential survival markers. This was a retrospective cohort study of mCRC patients who participated in the trifluridine/tipiracil early clinical experience programme in Spain. The primary outcome was overall survival (OS). Associations between OS and patient characteristics were assessed using multivariate Cox regression analyses. A total of 379 patients were included in the study. Trifluridine/tipiracil was administered for a median of 3.0 cycles and discontinued mainly due to disease progression (79.2%). The median OS was 7.9 months, with a 12-month OS rate of 30.5%. Cox analyses revealed that the following variables independently enhanced OS: ≤2 metastatic sites, no liver metastasis, alkaline phosphatase <, 300 IU, trifluridine/tipiracil dose reductions, and neutrophil/lymphocyte ratio <, 5. Grade ≥ 3 toxicities were reported in 141 (37.2%) patients, including mainly afebrile neutropaenia (23.2%), anaemia (12.1%), and thrombocytopaenia (5.3%). This study supports the real-life efficacy and safety of trifluridine/tipiracil for refractory mCRC and identifies tumour burden, liver metastasis, alkaline phosphatase, dose reductions, and neutrophil/lymphocyte ratio as survival markers.
- Published
- 2021
8. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study
- Author
-
J. Sastre, P. García-Alfonso, J.M. Viéitez, M.T. Cano, F. Rivera, J.J. Reina-Zoilo, A. Salud-Salvia, G. Quintero, L. Robles-Díaz, M.J. Safont, A. La Casta, S. Gil, E. Polo, E. Asensio-Martínez, B. García-Paredes, R.L. López, M. Guillot, M. Valladares-Ayerbes, E. Aranda, E. Díaz-Rubio, P. Jiménez, E. Aranda Aguilar, A. Gómez, S. Gil Calle, A. Salud, M. Valladares, B. Graña, J.J. Reina, E. González Flores, M. Salgado, E. Grande, C. Guillén, R. Garcia Carbonero, M.J. Flor, S. Arévalo, R. López López, H. Manzano, X. Hernández Yagüe, A. Arrivi, E. Falcó, J. Gallego, P. Escudero, I. Cabezas, A. Juárez, E. Gálvez, C. Grávalos, L. Robles, R. Dueñas, J.M. Campos, A. Albert, P. Salinas, C. Montagut, M. Provencio, A. Ruiz Casado, J. Muñoz, M. Gil Raga, M.R. Chilet, F.J. González González, B. Massutí, A. López, J. Aparicio, M. Marín, J. Alfaro, M. Zanui, D. Gutiérrez Abad, A.M. García Tapiador, C. García-Girón, J. Molina Saera, E. Torres Sánchez, I. López, C. Bosch, J. Valero, P. Martínez de Prado, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), [Sastre,J, García-Paredes,B, Díaz-Rubio,E] Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC). [García-Alfonso,P] Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid. [Viéitez,JM] Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, [Cano,MT, Aranda,E] Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Cordoba. [Rivera,F] Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander. [Reina-Zoilo,JJ] Medical Oncology, Complejo Hospitalario Virgen de la Macarena, Seville. [Salud-Salvia,A] Hospital Universitario Arnau de Vilanova de Lleida, Lleida. [Quintero,G] Medical Oncology, Hospital Lucus Augusti, Lugo. [Robles-Díaz,L] Medical Oncology, Hospital 12 de Octubre, Madrid. [Safont,MJ] Medical Oncology, Hospital General Universitario de Valencia, Valencia. [La Casta,A] Medical Oncology, Hospital de Donostia, Guipúzcoa. [Gil,S] Medical Oncology, Hospital Universitario Regional y Virgen de la Victoria, Malaga. [Polo,E] Medical Oncology, Hospital Miguel Servet, Zaragoza. [Asensio-Martínez,E] Medical Oncology, Hospital General Universitario de Elche, Alicante. [López,RL] Medical Oncology, University Clinical Hospital and Health Research Institute (IDIS), CIBERONC, Santiago de Compostela University School of Medicine, Santiago de Compostela. [Guillot,M] Medical Oncology, Hospital Son Espases, Palma de Mallorca. [Valladares-Ayerbes,M] Medical Oncology, Complejo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica (INIBIC), A Coruña, Spain., This work was supported by Roche Farma S.A (no grant number). Medical writing support was funded by Roche Farma S.A and provided by H. Lamb and L. Miller of Miller Medical Communications Ltd., and UAM. Departamento de Medicina
- Subjects
Oncology ,Cancer Research ,Colorectal cancer ,Terapia dirigida ,Cetuximab ,Phases of clinical research ,Chemicals and Drugs::Heterocyclic Compounds::Alkaloids::Camptothecin [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings] ,Targeted therapy ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Neoplasias colorrectales ,Antineoplastic Combined Chemotherapy Protocols ,Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines::Pyrimidinones::Uracil::Fluorouracil [Medical Subject Headings] ,Original Research ,Hazard ratio ,Neoplastic Cells, Circulating ,targeted therapy ,Bevacizumab ,Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Phosphatidylinositol 3-Kinases::Phosphatidylinositol 3-Kinase::Class I Phosphatidylinositol 3-Kinases [Medical Subject Headings] ,FOLFIRI ,Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropenia [Medical Subject Headings] ,Colorectal Neoplasms ,Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Asthenia [Medical Subject Headings] ,medicine.drug ,Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis::Neoplastic Cells, Circulating [Medical Subject Headings] ,Proto-Oncogene Proteins B-raf ,medicine.medical_specialty ,Medicina ,Class I Phosphatidylinositol 3-Kinases ,colorectal cancer ,Neutropenia ,Neoplastic cells circulating ,BRAF ,Internal medicine ,medicine ,Humans ,neoplasms ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [Medical Subject Headings] ,business.industry ,Chemicals and Drugs::Enzymes and Coenzymes::Coenzymes::Tetrahydrofolates::Formyltetrahydrofolates::Leucovorin [Medical Subject Headings] ,Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings] ,PIK3CA ,medicine.disease ,digestive system diseases ,Irinotecan ,Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Signs and Symptoms, Digestive::Diarrhea [Medical Subject Headings] ,Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Serine-Threonine Kinases::MAP Kinase Kinase Kinases::raf Kinases::Proto-Oncogene Proteins B-raf [Medical Subject Headings] ,Camptothecin ,business ,Células neoplásicas circulantes ,RAS - Abstract
Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM, Background We explored the influence of BRAF and PIK3CA mutational status on the efficacy of bevacizumab or cetuximab plus 5-fluorouracil/leucovorin and irinotecan (FOLFIRI) as first-line therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). Patients and methods VISNÚ-2 was a multicentre, randomised, phase II study. Patients with RAS wild-type mCRC and 1), and allocated to bevacizumab (5 mg/kg every 2 weeks) or cetuximab (400 mg/m2 then 250 mg/m2 weekly) plus FOLFIRI [irinotecan 180 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 (bolus) then 2400 mg/m2 (46-h continuous infusion) every 2 weeks]. The primary endpoint was progression-free survival (PFS). All analyses were exploratory. Results Two hundred and forty patients with BRAF/PIK3CA wild-type (n = 196) or BRAF- and/or PIK3CA-mutated tumours (n = 44) were enrolled. Median PFS was 12.7 and 8.8 months in patients with BRAF/PIK3CA wild-type and BRAF/PIK3CA-mutated tumours, respectively [hazard ratio (HR) = 1.22; 95% confidence interval (CI) 0.80-1.85; P = 0.3602]. In the BRAF- and/or PIK3CA-mutated cohort, median PFS was 2.8, 8.8 and 15.0 months in patients with BRAF/PI3KCA-mutated (n = 8), BRAF-mutated/PI3KCA wild-type (n = 16) and BRAF wild-type/PI3KCA-mutated (n = 20) tumours, respectively (P = 0.0002). PFS was similar with bevacizumab plus FOLFIRI versus cetuximab plus FOLFIRI in BRAF/PIK3CA wild-type (HR = 0.99; 95% CI 0.67-1.45; P = 0.9486) and BRAF/PIK3CA-mutated tumours (HR = 1.11; 95% CI 0.53-2.35; P = 0.7820). The most common grade 3/4 treatment-related adverse events were neutropenia, diarrhoea and asthenia in both treatment groups. Conclusions BRAF/PIK3CA status influences outcomes in patients with RAS wild-type mCRC but does not appear to assist with the selection of first-line targeted therapy, This work was supported by Roche Farma S.A (no grant number). Medical writing support was funded by Roche Farma S.A and provided by H. Lamb and L. Miller of Miller Medical Communications Ltd.
- Published
- 2021
9. Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
- Author
-
E. Falcó, Ana Fernandez-Montes, Francis Esposito, Hermini Manzano, Pilar Escudero, Sara Serrano, Ana Ruiz-Casado, and Jorge Aparicio
- Subjects
Oncology ,medicine.medical_specialty ,targeted agents ,Bevacizumab ,Colorectal cancer ,medicine.medical_treatment ,lcsh:Medicine ,Unresectable disease ,colorectal cancer ,Review ,Malignancy ,chemotherapy ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,First line therapy ,Growth factor receptor ,Randomized controlled trial ,law ,Internal medicine ,medicine ,030212 general & internal medicine ,Chemotherapy ,business.industry ,lcsh:R ,General Medicine ,medicine.disease ,030220 oncology & carcinogenesis ,business ,metastatic disease ,medicine.drug - Abstract
Colorectal cancer (CRC) is a commonly diagnosed malignancy. The prognosis of patients with unresectable, metastatic colorectal cancer (mCRC) is dismal and medical treatment is mainly palliative in nature. Although chemotherapy remains the backbone of treatment, the landscape is changing with the understanding of its heterogeneity and molecular biology. First-line therapy relies on a combination of chemotherapy and targeted therapies, according to clinical patient characteristics and tumor molecular profile. Here we review current evidence from randomized clinical trials for using chemotherapy doublets or triplets, and for the addition of bevacizumab or anti-epidermal growth factor receptor (EGFR) agents. Novel therapies developed for small, selected populations are also discussed.
- Published
- 2020
10. A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective
- Author
-
Agnes Benedict, Lucjan Wyrwicz, Josep M. Borràs, Z. Maravic, Eloy Espin-Basany, Jadranka Stanisic Trenevski, Agota Petrányi, Alfredo Carrato, Anna Horváth, Liesbeth Lemmens, Ana Ruiz-Casado, Vassiliki Fotaki, and Iga Rawicka
- Subjects
Cancer Research ,medicine.medical_specialty ,Medical screening ,Colorectal cancer ,unmet needs ,Eastern Europe ,lcsh:RC254-282 ,Unmet needs ,Càncer colorectal ,Surveys and Questionnaires ,Health care ,Medicine ,Humans ,Information provision ,Original Research ,Hungary ,business.industry ,Crc screening ,metastatic colorectal cancer ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Eastern european ,Cribratge ,Oncology ,Family medicine ,patient journey ,Patient survey ,Poland ,business ,Colorectal Neoplasms ,Serbia ,patient survey - Abstract
Background Despite being highly preventable and treatable if diagnosed early, colorectal cancer (CRC) remains the second leading cause of cancer-related death in Europe. Limited information is available from the patient perspective on the persisting unmet needs of the journey of the patient with CRC. Objective To capture European metastatic CRC (mCRC) patients’ insights during the patient journey (prediagnosis; diagnosis; postdiagnosis) through a patient survey. Methods In total, 883 patients from 15 European countries participated. Participants were divided into four groups from Hungary, Poland, Serbia and ‘other European countries’ (n=103, 163, 170 and 447 patients, respectively). Results General awareness of CRC and its symptoms prediagnosis varied among groups, with patients from Poland recording the lowest levels. Screening practices and attitudes also varied; while more patients from Serbia had been invited to CRC screening (~15%) compared with the other groups, the ones not invited claimed mostly (~20%) that would not have attended if they had been invited. Whereas most patients were diagnosed within a month after the first consultation/positive screening, the percentages varied substantially being lowest among patients in Poland (~30%) and Serbia (~25%). Although CRC-related information provision varied, with most informed patients from Hungary (~90%) and least from Serbia (~50%), all groups requested an easier-to-understand language by the healthcare team. Approximately 50% of patients from Eastern Europe had to wait longer than a month to receive treatment, in contrast to ~30% from other European countries. All groups emphasised the unmet need for support from psychologists and other patients. Conclusions Our survey reveals the key aspects of the journey of the patient with mCRC and highlights the areas of similarities and differences between patients with mCRC from Eastern Europe versus those from other European countries as well as among patients from different Eastern European countries, calling for improvement particularly around awareness, screening, treatment availability, communication and support networks.
- Published
- 2020
11. LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
- Author
-
Julien Taieb, E. Elez Fernandez, Axel Grothey, E. Carriere Roussel, M. Van den Eynde, A. Ruiz Casado, Takayuki Yoshino, Z. Issiakhem, J. Vedovato, B. Jean, Evaristo Maiello, Thierry André, T. Kato, E. Van Cutsem, C. Cahuzac, Paul Ross, Janet Graham, Rona Yaeger, J. Ruffinelli, R. Vera, J. Tabernero, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'hématologie, and UCL - (SLuc) Service d'hépato-gastro-entérologie
- Subjects
Cetuximab ,business.industry ,Colorectal cancer ,Mutant ,Phases of clinical research ,Binimetinib ,Hematology ,medicine.disease ,BRAF V600E ,chemistry.chemical_compound ,chemistry ,Oncology ,Encorafenib ,Cancer research ,Medicine ,business ,medicine.drug - Abstract
Background BRAFV600E mutations are identified in 8-15% of metastatic colorectal cancer (mCRC) patients and confer a poor prognosis. In patients with BRAFV600E-mutant mCRC, the combination of encorafenib (ENCO) + cetuximab (CETUX) ± binimetinib (BINI) in second- and third-line therapy has demonstrated improved outcomes compared to standard therapies (BEACON CRC study). The ANCHOR CRC study was designed to investigate the triplet combination (ENCO + BINI + CETUX) in the first line setting of this population. Methods ANCHOR CRC is an open-label, single arm, two-stage design, phase 2 study in patients with BRAFV600E-mutant mCRC who did not receive any prior systemic therapy for metastatic disease. Patients received ENCO 300 mg orally QD + BINI 45 mg orally BID and CETUX IV weekly (250mg/m2 after a first dose of 400mg/m2) for the first 28 weeks and then once every two weeks (500mg/m2). The primary endpoint was confirmed Objective Response Rate (cORR) based on local review; secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS) and safety. Analysis for Stage 1 was performed after the first 40 evaluable patients with a centrally confirmed BRAFV600E mutation had completed four post-baseline tumor assessments or discontinued. At least 12 responses in Stage 1 were needed to initiate Stage 2 and to enroll 50 additional patients to complete the recruitment with a total of 90 patients in the study. Stage 1 analysis results are presented here. Results Forty-one BRAFV600E-mutant mCRC patients with a median age of 67 years old (61% of the patients were ≥ 65 years old) were enrolled in Stage 1 and received the triplet combination as first line metastatic treatment. At study entry, 56% of patients presented with ECOG PS 1, 78% had metastases to at least 2 organs and 51% had peritoneal metastasis. Forty patients were evaluable for efficacy (BRAFV600E mutation was not centrally confirmed for one patient). The investigator assessed cORR was 50% (95% confidence interval [CI], 33.8-66.2) with 85% of patients having a decrease in tumor size. The investigator measured median PFS was 4.9 months (95% CI, 4.4-8.1). Adverse events were consistent with those observed in prior studies with this triplet combination. Grade 3 or higher adverse events were seen in 68% of patients, the most common being: diarrhea (15%), acute kidney injury (12%) and anemia (12%). Conclusion The ANCHOR CRC study is the first prospective study using a BRAF inhibitor-based therapy in first line BRAFV600E-mutant mCRC. Despite the high risk features of the population enrolled in Stage 1, including high proportion of patients ≥ 65 years old and advanced stage at diagnosis (multiple metastatic sites with frequent peritoneal carcinomatosis), most patients had tumor regression. The safety profile was acceptable and toxicities remained manageable. The Stage 1 analysis exceeded the minimal number of confirmed responses and proceeded to enroll 54 additional patients in Stage 2 to complete the study recruitment.
- Published
- 2020
12. Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study
- Author
-
Vera, Ruth, Luisa Gomez, Maria, Ramon Ayuso, Juan, Figueras, Joan, Garcia-Alfonso, Pilar, Martinez, Virginia, Lacasta, Adelaida, Ruiz-Casado, Ana, Jose Safont, Maria, Aparicio, Jorge, Manuel Campos, Juan, Carlos Camara, Juan, Martin-Richard, Marta, Montagut, Clara, Pericay, Carles, Maria Vieitez, Jose, Falco, Esther, Jorge, Monica, Marin, Miguel, Salgado, Mercedes, Viudez, Antonio, and Spanish Multidisciplinary Grp Dige
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Bevacizumab ,Colorectal cancer ,bevacizumab ,lcsh:RC254-282 ,Article ,Capecitabine ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Rectal Adenocarcinoma ,Pathological ,computed tomography-based morphological criteria ,Performance status ,business.industry ,metastatic colorectal cancer ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Oxaliplatin ,antiangiogenics ,030104 developmental biology ,030220 oncology & carcinogenesis ,Metastasectomy ,business ,medicine.drug ,neoadjuvant chemotherapy - Abstract
Background: The prospective phase IV AVAMET study was undertaken to correlate response evaluation criteria in solid tumors (RECIST)-defined response rates with computed tomography-based morphological criteria (CTMC) and pathological response after liver resection of colorectal cancer metastases. Methods: Eligible patients were aged &ge, 18 years, with Eastern Cooperative Oncology Group (ECOG) performance status 0/1 and histologically-confirmed colon or rectal adenocarcinoma with measurable liver metastases. Preoperative treatment was bevacizumab (7.5 mg on day 1) + XELOX (oxaliplatin 130 mg/m2, capecitabine 1000 mg/m2 bid on days 1&ndash, 14 q3w). After three cycles, response was evaluated by a multidisciplinary team. Patients who were progression-free and metastasectomy candidates received one cycle of XELOX before undergoing surgery 3&ndash, 5 weeks later, followed by four cycles of bevacizumab + XELOX. Results: A total of 83 patients entered the study, 68 were eligible for RECIST, 67 for CTMC, and 51 for pathological response evaluation. Of these patients, 49% had a complete or partial RECIST response, 91% had an optimal or incomplete CTMC response, and 81% had a complete or major pathological response. CTMC response predicted 37 of 41 pathological responses versus 23 of 41 responses predicted using RECIST (p = 0.008). Kappa coefficients indicated a lack of correlation between the results of RECIST and morphological responses and between morphological and pathological response rates. Conclusion: CTMC may represent a better marker of pathological response to bevacizumab + XELOX than RECIST in patients with potentially-resectable CRC liver metastases.
- Published
- 2020
13. Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
- Author
-
Aparicio J, Esposito F, Serrano S, Falco E, Escudero P, Ruiz-Casado A, Manzano H, and Fernandez-Montes A
- Subjects
targeted agents ,colorectal cancer ,chemotherapy ,metastatic disease - Abstract
Colorectal cancer (CRC) is a commonly diagnosed malignancy. The prognosis of patients with unresectable, metastatic colorectal cancer (mCRC) is dismal and medical treatment is mainly palliative in nature. Although chemotherapy remains the backbone of treatment, the landscape is changing with the understanding of its heterogeneity and molecular biology. First-line therapy relies on a combination of chemotherapy and targeted therapies, according to clinical patient characteristics and tumor molecular profile. Here we review current evidence from randomized clinical trials for using chemotherapy doublets or triplets, and for the addition of bevacizumab or anti-epidermal growth factor receptor (EGFR) agents. Novel therapies developed for small, selected populations are also discussed.
- Published
- 2020
14. Physical activity and nutritional interventions and health-related quality of life in colorectal cancer survivors: a review
- Author
-
Ana Ruiz-Casado, Alejandro Lucia, Luisa Soares-Miranda, and Sandra Abreu
- Subjects
Health related quality of life ,Gerontology ,Chronic disease ,Quality of life (healthcare) ,Nutritional Interventions ,business.industry ,Colorectal cancer ,Physical activity ,Medicine ,business ,medicine.disease ,Sentence - Abstract
Introduction: Once often perceived as a death sentence, colorectal cancer (CRC) is now a frequently treatable illness for most and a chronic disease for many. The number of people living with a dia...
- Published
- 2018
15. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
- Author
-
Élez, Elena, Gómez-España, María Auxiliadora, Grávalos, Cristina, García-Alfonso, Pilar, Ortiz-Morales, María José, Losa, Ferrán, Díaz, Inmaculada Alés, Graña, Begoña, Toledano-Fonseca, Marta, Valladares-Ayerbes, Manuel, Polo, Eduardo, Salgado, Mercedes, Martínez de Castro, Eva, Safont, María José, Salud, Antonieta, Ruiz-Casado, Ana, Tabernero, Josep, Riesco, María del Carmen, Rodriguez-Ariza, Antonio, and Aranda, Enrique
- Subjects
THERAPEUTIC use of antineoplastic agents ,FOLINIC acid ,CLINICAL trials ,CAMPTOTHECIN ,CELL receptors ,COLORECTAL cancer ,FLUOROURACIL ,PSYCHOLOGICAL tests ,VASCULAR endothelial growth factors ,RECOMBINANT proteins - Abstract
Background: Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated. We assessed aflibercept plus FOLFIRI, investigating the biomarker role of baseline vascular endothelial growth factor A (VEGF-A) and angiotensin-converting enzyme (ACE).Methods: Phase II trial in oxaliplatin-treated mCRC patients who received aflibercept plus FOLFIRI. The reported 135 ng/mL ACE cut-off was used and ROC analysis was performed to assess the optimal VEGF-A cut-off for progression-free survival (PFS). Overall survival (OS), time to progression (TTP), time to treatment failure (TTF), overall response rate (ORR) and disease control rate (DCR) were also assessed.Results: In total, 101 patients were followed for a median of 12 (6-17) months. The 1941 pg/mL VEGF-A was an optimal cut-off, with a longer median PFS when VEGF-A was <1941 versus ≥1941 pg/mL (9 versus 4 months). Patients with VEGF-A < 1941 pg/mL showed longer median OS (19 versus 8 months), TTP (9 versus 4 months) and TTF (8 versus 4 months), along with higher ORR (26% versus 9%) and DCR (81% versus 55%). No differences were identified according to ACE levels.Conclusions: This study supports aflibercept plus FOLFIRI benefits, suggesting VEGF-A as a potential biomarker to predict better outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
16. O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer
- Author
-
E. Carriere Roussel, Jeroen Dekervel, Rona Yaeger, Elena Elez, J. Ruffinelli, M. Groc, Takayuki Yoshino, Evaristo Maiello, Thierry André, Julien Taieb, J. Vedovato, A. Ruiz Casado, Axel Grothey, J. Tabernero, Paul Ross, I. Klauck, Janet Graham, T. Kato, and E. Van Cutsem
- Subjects
Cetuximab ,Colorectal cancer ,business.industry ,Mutant ,Phases of clinical research ,Binimetinib ,Hematology ,medicine.disease ,BRAF V600E ,chemistry.chemical_compound ,Oncology ,chemistry ,Encorafenib ,Cancer research ,medicine ,business ,medicine.drug - Published
- 2021
17. 474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC)
- Author
-
Isidro Machado, Carlos Fernández-Martos, Vicente Alonso-Orduña, E. Galvez, Carlos Horndler, O. Higuera Gomez, Jorge Aparicio, Louis Vermeulen, R. Leno, V. Heredia Soto, I. Sevilla García, Jaime Feliu, S. ten Hoorn, Ana Ruiz-Casado, Miriam Cuatrecasas, A. Fernández Montes, Marta Mendiola, M. Martin-Richard, M. Méndez, and Juan Maurel
- Subjects
Oncology ,medicine.medical_specialty ,Colorectal cancer ,business.industry ,Internal medicine ,medicine ,Immunohistochemistry ,Hematology ,medicine.disease ,business - Published
- 2020
18. Noncirrhotic portal hypertension: An under-reported late adverse event of SIRT in metastatic colorectal cancer patients
- Author
-
Ana Ruiz-Casado, Clara Salas, Mercedes Mitjavila, Lourdes Gutierrez, Elba Llop, and Santiago Méndez
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Time Factors ,Colorectal cancer ,Biopsy ,Brachytherapy ,lcsh:RC254-282 ,Late toxicity ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Hypertension, Portal ,medicine ,Humans ,SIRT ,Radiology, Nuclear Medicine and imaging ,In patient ,Yttrium Radioisotopes ,Adverse effect ,Radiation Injuries ,Aged ,regenerative nodular hyperplasia ,business.industry ,Incidence (epidemiology) ,Selective internal radiation therapy ,portal hypertension ,General Medicine ,Chemoradiotherapy, Adjuvant ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Microspheres ,Oxaliplatin ,Treatment Outcome ,030220 oncology & carcinogenesis ,Portal hypertension ,030211 gastroenterology & hepatology ,Female ,business ,Colorectal Neoplasms ,liver metastases ,medicine.drug - Abstract
Introduction: Selective internal radiation therapy (SIRT) is increasingly used in different scenarios. Although portal hypertension (PHT) has been described as a nonclinically relevant finding after SIRT, its real incidence could have been neglected due to the nature of the diseases for which SIRT is indicated. Case Reports: Here we report three cases with clinically relevant late PHT after treatments including SIRT and oxaliplatin among others. Discussion: The sequential use of oxaliplatin and SIRT in patients with colorectal cancer metastases could have additive effects on the liver.
- Published
- 2019
19. 471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score
- Author
-
Jorge Aparicio, A. Sesma, E. Galvez, Jaime Feliu, H. Manzano, Carlos Fernández-Martos, Jesús Gallego, Faustina Torres, Rosa Gallego, Juan Maurel, H. Oliveres, Vicente Alonso-Orduña, Francis Esposito, M. Martin-Richard, J. Alcaide-Garcia, A. Fernández-Montes, E. Falcó, Ana Ruiz-Casado, Antonieta Salud, and E. Seguí
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,Internal medicine ,medicine ,Identification (biology) ,Hematology ,business ,medicine.disease ,Prognostic score - Published
- 2020
20. Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy : combined analysis of two randomized controlled studies
- Author
-
Peter Gibbs, Volker Heinemann, Navesh K. Sharma, Julien Taieb, Jens Ricke, Marc Peeters, Michael Findlay, Bridget Robinson, Christopher Jackson, Andrew Strickland, Val Gebski, Mark Van Buskirk, Huaqing Zhao, Guy van Hazel, Michael Brown, Matthew Burge, Giuseppe Cardaci, Stephen Clarke, Paul Eliadis, Tom Ferguson, Vinod Ganju, Philip James, Chris Karapetis, Winston Liauw, Gavin Marx, Marco Matos, Louise Nott, Nick Pavlakis, Alex Powell, Timothy Price, David Ransom, Eva Segelov, Jenny Shannon, Nimit Singhal, Euan Walpole, Michel Craninx, Thierry Delaunoit, Amélie Deleporte, Michel Ferrante, Karen Geboes, Alain Hendlisz, Koen Hendrickx, Marc De Man, Els Monsaert, Veerle Moons, Marc Polus, Eveline Boucher, Jacques Balosso, Patrick Chevallier, Samy Louafi, Marc Pracht, Christine Rebischung, Denis Smith, Eric Terrebonne, Harald-Robert Bruch, Gerald Gehbauer, Thomas Helmberger, Yon-Dschun Ko, Hendrik Kröning, Frank Lammert, Arnd Nusch, Stefan Pluntke, Karsten Ridwelski, Jorge Riera-Knorrenschild, Hanno Riess, Jorge Ramon Riera, Tilmann Sauerbruch, Klemens Scheidhauer, Oliver Stötzer, Klaus Tatsch, Ursula Vehling-Kaiser, Thomas Vogl, Alex Beny, Ravit Geva, Einat Shacham-Shmueli, Salomon Stemmer, Thomas Tichler, Ido Wolf, Bruna Angelelli, Andrea Martoni, Michael P.N. Findlay, Richard Isaacs, Anne O’Donnell, David Perez, Bridget A. Robinson, Javier Rodríguez, Ruth Vera-Garcia, Pradip Amin, Daniel Bloomgarden, James Bui, James Carlisle, Seungjean Chai, Yi-Jen Chen, Michael Chuong, Andrew Coveler, Francis Facchini, Gary Frenette, Jacob Frick, Michael Garofalo, Benjamin George, Michael Gordon, Seza Gulec, James Hannigan, Matthew Holtzman, Andreas Kaubisch, Adeel Kaiser, Todd Kooy, Steven Limentani, Jeffrey Margolis, Robert Martin, Howard Ozer, Siddarth Padia, William Rilling, Michael Savin, Elyse Schneiderman, Grant Seeger, Navesh Sharma, Stephen Shibata, Randall Smith, Eric Wang, Samuel Whiting, Morteza Aghmesheh, Mathew Burge, Prasad Cooray, Kynan Feeney, Lionel Lim, Madhu Singh, Craig Underhill, Amelie Deleporte, Aurelie Durand, Sandrine Faivre, Aurelie Ferru, Pascal Hammel, Christoph Bremer, Maike De Wit, Hubert Ayala, Norman Heching, Adi Shani, Cristina Granetto, Gianluca Masi, Stefania Mosconi, Gianmauro Numico, Antonio Trogu, Yeul Hong Kim, Han Sae-Won, Chris Jackson, Anne O'Donnell, Maria Fragoso, Iain Tan, Ana Ruiz Casado, Jin Tung Liang, Jin Hwang Liu, Steven Ades, Miklos Auber, Patrick Boland, Charles Bowers, Martin Crain, Kyran Dowling, Renuka Iyer, Lynn Ratner, Federico Sanchez, Patricia Stoltzfus, Mark Westcott, SIRFLOX Global Trial Investigator, and FOXFIRE Global Trial Investigator
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,Brachytherapy ,Left-sided primary ,030218 nuclear medicine & medical imaging ,Cohort Studies ,03 medical and health sciences ,Folinic acid ,0302 clinical medicine ,Internal medicine ,Overall survival ,Right-sided primary ,SIRT ,mCRC ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Survival rate ,Aged ,Chemotherapy ,business.industry ,Selective internal radiation therapy ,Liver Neoplasms ,Gastroenterology ,Chemoradiotherapy ,medicine.disease ,Prognosis ,Primary tumor ,Oxaliplatin ,Survival Rate ,030220 oncology & carcinogenesis ,Female ,Human medicine ,business ,Colorectal Neoplasms ,medicine.drug ,Follow-Up Studies - Abstract
The primary tumor side is emerging as a prognostic factor for patients with liver metastatic colorectal cancer (mCRC). In a combined analysis of data from 2 randomized studies, the addition of selective internal radiation therapy to first-line chemotherapy in patients with mCRC was associated with statistically and clinically significant overall survival gains for patients with a right-sided primary tumor. Background: The primary tumor side is emerging as a major prognostic factor for patients with metastatic colorectal cancer (mCRC). We examined the survival data from 2 randomized studies to determine whether the outcomes differ between patients with mCRC with right-sided primary (RSP) tumors and those with left-sided primary (LSP) tumors after selective internal radiation therapy (SIRT) plus mFOLFOX6 (folinic acid [leucovorin], 5-fluorouracil, oxaliplatin) chemotherapy, versus chemotherapy alone. Patients and Methods: Separate and combined analyses were performed on the data from the SIRFLOX and FOXFIRE global trials, which compared chemotherapy plus SIRT with chemotherapy alone for patients with mCRC liver metastases. The primary tumor side data were prospectively collected. The principal outcome measure was overall survival (OS) stratified by treatment and primary tumor side. Results: In the combined analysis of all 739 patients enrolled, SIRT had no effect on OS (median OS, 24.3 vs. 24.6 months; hazard ratio [HR], 1.021; P = .810). For the 179 patients (24.2%) with a RSP tumor, OS was improved with the addition of SIRT (median, 22.0 vs. 17.1 months HR, 0.641; P = .008). The addition of SIRT was not associated with a significant difference in OS among the 540 patients with a LSP tumor (median, 24.6 vs. 26.6 months; HR, 1.120; P = .264). A test of treatment interaction by primary tumor side was statistically significant for RSP and SIRT (P = .002). Conclusion: The addition of SIRT for patients with RSP tumors, but not for those with LSP tumors, was associated with a statistically and clinically significant OS gain. (C) 2018 Elsevier Inc. All rights reserved.
- Published
- 2018
21. RAS analysis of circulating tumor cells from advanced colorectal cancer using BEAMing technology
- Author
-
Miguel Jhonatan Sotelo Lezama, Ana López-Alfonso, Javier Sastre, Eduardo Díaz-Rubio, Beatriz Mediero-Valeros, Virginia De la Orden-García, Ana Ruiz-Casado, Antonio Carlos Sánchez Ruiz, Mateo Paz Cabezas, Santiago Cabezas-Camarero, Vanesa García-Barberán, and Isabel Díaz-Millán
- Subjects
Advanced colorectal cancer ,Cancer Research ,Circulating tumor cell ,Oncology ,business.industry ,Colorectal cancer ,Cancer research ,Medicine ,business ,medicine.disease ,digestive system diseases - Abstract
e15151 Background: RAS mutations predict a lack of response to anti-EGFR therapies in metastatic colorectal cancer (mCRC). BEAMing technology is useful for detecting hot-spot mutations in ctDNA in mCRC. Analysis of these mutations in DNA from Circulating Tumor Cells (CTC) may increase the predictive value in mCRC patients (pts). Our aim was to explore the feasibility of studying RAS status using BEAMing in DNA from CTC. Methods: First, spiking experiments (SE) using wild-type (WT) and KRAS-mutated (MUT) cell lines were performed to establish the limit of detection (LOD) for RAS analysis with BEAMing. Second, SE were performed with CTC collected by CellCelector (removes non-CTC background achieving 100% purity of CTC). Finally, BEAMing was used for RAS analysis in ctDNA and in DNA from CTC isolated either with IsoFlux or with CellCelector in 9 mCRC pts with confirmed RAS mutation in primary tumor. Total DNA from CTC was preamplified using RepliG. Results: In SE, 10 and 5 KRAS MUT-cells using different backgrounds of WT-cells (10-0.2% MUT-cells) were detected using BEAMing. However, 3 and 1 MUT-cells (0.009-0%) were not detected. In SE of CTCs collected with CellCelector, BEAMing detected KRAS mutations with 50, 20, 10, 6, 4, 2 and 1 cell (MAF: 23.8%±3.8). A mutation (codon 13) was detected in CTC from one patient positive in tissue and ctDNA (CellCelector; 15 CTCs; MAF: 11.4%). Discordant results were found in 8 patients when CTCs were isolated using Isoflux (min: 0, max: 9 CTCs). CTC from another patient were possibly mutated but WT in ctDNA. Conclusions: This pilot study indicates that RAS mutations can be detected in CTCs using BEAMing. Reducing the non-CTC cellular background may be needed in cases with low CTC number. Molecular information provided by CTC and ctDNA may prove complementary and useful for taking therapeutic decisions in mCRC. These results merit confirmation in larger, prospective studies.
- Published
- 2019
22. Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report
- Author
-
J Muñoz-Rodriguez, Ana Ruiz-Casado, and A Gonzaga-López
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Bevacizumab ,Colorectal cancer ,Recombinant Fusion Proteins ,Leucovorin ,Necrotising fasciitis ,Angiogenesis inhibitor ,Antineoplastic Agents ,030226 pharmacology & pharmacy ,Colorectal neoplasms ,Ramucirumab ,03 medical and health sciences ,chemistry.chemical_compound ,Fatal Outcome ,0302 clinical medicine ,Internal medicine ,Regorafenib ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Fasciitis, Necrotizing ,Aflibercept ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Irinotecan ,Receptors, Vascular Endothelial Growth Factor ,Online Case Report ,chemistry ,030220 oncology & carcinogenesis ,FOLFIRI ,Camptothecin ,Surgery ,Fluorouracil ,business ,Fournier Gangrene ,medicine.drug - Abstract
Anti-angiogenics have become an important part of the treatment of several types of tumours such as ovarian, breast, lung and colorectal cancer. Necrotising fasciitis has been reported with bevacizumab but no cases have been reported with aflibercept, ramucirumab or regorafenib in patients with colorectal cancer. Necrotising fasciitis is a rare complication affecting one in 5000 bevacizumab users. We report the case of a 64-year-old man with stage IV rectosigmoid cancer under treatment with folinic acid, fluorouracil and irinotecan (FOLFIRI) and aflibercept, who developed a Fournier’s gangrene.
- Published
- 2017
23. Autonomy support in an exercise intervention with colorectal cancer patients during chemotherapy: a qualitative perspective.
- Author
-
Romero-Elías, María, González-Cutre, David, Ruiz-Casado, Ana, Tortosa-Martínez, Juan, and Beltrán-Carrillo, Vicente J.
- Subjects
- *
EXERCISE therapy , *COLORECTAL cancer , *CANCER patients , *MEDICAL personnel , *AUTONOMY (Psychology) - Abstract
AbstractObjectiveMethods and MeasuresResultsConclusionPhysical activity (PA) has emerged as an important element of supportive care for cancer patients, but few patients engage with exercise. Considering that autonomy support is associated with healthy lifestyles, it would be useful to know the specific autonomy-supportive techniques that can help to encourage PA in colorectal cancer (CRC) patients. This study aims to qualitatively explore autonomy support perceptions through a self-determination-theory-based exercise program (FIT-CANCER) with CRC patients during chemotherapy treatment.A total of 27 participants were included, 16 CRC patients, six relatives, and five healthcare professionals. Qualitative data from semi-structured interviews and observational field notes were analyzed with thematic analysis.Three main themes were identified: Healthcare professionals encouraging enrollment in the exercise program, Relatives supporting attendance to the exercise sessions, Exercise instructor favoring adherence to the exercise program. The different subthemes showed autonomy-supportive techniques from these social agents to promote CRC patients’ participation in the exercise program.The present research showed the importance of autonomy support from healthcare professionals, relatives and the exercise instructor to promote the initiation and maintenance of CRC patients’ PA behavior and improve their quality of life, health and well-being. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)
- Author
-
J. Garcia-Corbacho, M. Español Rego, R. Cabezón, Jorge Aparicio, Miquel Lozano, Carlos Fernández-Martos, Juan Maurel, E. Elez Fernandez, A. Ruiz Casado, Jessica Cid, X. García de Albéniz, Nohra Cecilia Rodríguez, D. Benitez Ribas, Pilar Escudero, A. Ginés, V. Alonso, and L. Bianchi
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,Hematology ,Dendritic cell ,medicine.disease ,Avelumab ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Phase i ii ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,DNA mismatch repair ,business ,medicine.drug - Published
- 2018
25. Interim quality of life results from a real world European survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC)
- Author
-
L. Wyrwicz, A. Ruiz Casado, B. Karczmarek-Borowska, Z. Maravic, Anna Horváth, N. Muszbek, P. Rakonczai, and A. Carrato Mena
- Subjects
medicine.medical_specialty ,Quality of life (healthcare) ,Oncology ,Colorectal cancer ,business.industry ,Family medicine ,Interim ,medicine ,Hematology ,medicine.disease ,business ,Unmet needs - Published
- 2018
26. Recruitment for a survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC): Lessons from a European study
- Author
-
Z. Maravic, Tàrsila Ferro, C. González de Pedro, J. Stanisic Trenevski, A. Ruiz Casado, M. Méndez Otero, O. Rial, Josep M. Borràs, and J. Bokros
- Subjects
medicine.medical_specialty ,Oncology ,Colorectal cancer ,business.industry ,Family medicine ,medicine ,Hematology ,medicine.disease ,business ,Unmet needs - Published
- 2018
27. Cardio-respiratory fitness and functional performance in patients with a recent diagnosis of colorectal cancer
- Author
-
R. Gómez-Bravo, Maria Soriano, Lourdes Gutierrez Gutierrez Sanz, Alejandro Alvarez-Bustos, Jorge D. Sen, Carmen Fiuza-Luces, Ana Ruiz-Casado, Blanca De La Puente, Antonio Carlos Sánchez-Ruiz, Javier Ramos, Beatriz García, and Alejandro Lucia
- Subjects
Anamnesis ,Cancer Research ,medicine.medical_specialty ,Oncology ,Colorectal cancer ,business.industry ,medicine ,In patient ,Cardiorespiratory fitness ,Intensive care medicine ,medicine.disease ,business - Abstract
804 Background: Physical capability describes the ability to do the physical tasks of everyday living. Oncologists usually evaluate physical capability through anamnesis generating a performance status (PS) score. Some authors have proposed the use of cardiorespiratory reserve, muscular strength and objective evaluation of physical activity to avoid the subjective, unreliable and non-reproducible condition of PS. Methods: Patients with a recent diagnosis of colorectal cancer who accepted to participate were evaluated at the hospital setting. Walking speed was evaluated through both one-mile walk test and six-minute walk test. VO2max was calculated through the Kilne formula. Muscular strength was measured through dynamometry (hand-grip) and “sit to stand” test. Physical activity was objectively evaluated with accelerometers. Fatigue was evaluated through the PERFORM questionnaire (12-60). ECOG was evaluated by the medical oncologist. Results: 100 pats were recruited between March 15 and Jul 17. ECOG O/1/2 (80/14/2). 40 (40 %) were metastatic. Mean age 66 (25-81), Sex M/F; 68/32. Conclusions: Objective evaluation of physical condition is feasible at the hospital setting. There were no differences in BMI, heart rate, fatigue, muscular strength and objective functional performance (weekly PA) between localized and metastatic CRC. In metastatic pts with an excellent ECOG-PS the time to walk one mile and the estimated VO2max could be more sensitive than ECOG to evaluate the functional capacity impairment. In pts with cancer the One- mile walk test could be superior to the Six-minute walk to estimate the cardiorespiratory fitness. The objective evaluation of physical condition is a useful additional tool to select pts for aggressive therapies. [Table: see text]
- Published
- 2018
28. Risk of peritoneal carcinomatosis in pT4 and perforated colorectal cancer
- Author
-
Cecilia Peñacoba, Ana Ruiz-Casado, Joaquin M Muñoz-Rodríguez, Isabel Alonso, Arsenio S Movilla, Estíbalitz Pérez-Viejo, Ángel Serrano, and Lourdes Gutierrez Gutierrez Sanz
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,Internal medicine ,medicine ,Overall survival ,business ,medicine.disease ,Peritoneal carcinomatosis - Abstract
787 Background: Peritoneal carcinomatosis has a dismal prognosis with shorter overall survival than other isolated metastases. In selected patients, HIPEC shows encouraging results. However, early diagnosis continues to be a challenge. COLOPEC trial has been designed to determine the effectiveness of HIPEC in pT4 and perforated colon cancer expecting 25% of peritoneal carcinomatosis in the control arm. A routine second-look procedure in a pilot trial addressed to high-risk patients revealed peritoneal carcinomatosis in 13.3 % in the pT4 group and 50% in the perforation group. Methods: The aim of our study is to describe the risk of clinical/radiological peritoneal relapse in a high-risk population.This is a retrospective study. 711 patients diagnosed with colorectal cancer between 2012 and 2014 according to the hospital – based registry hospital, were reviewed. Patients with stage IV at diagnosis were excluded. 95 cases were considered as high-risk patients. We categorized different classes for pT4 (only), perforation (only) and pT4 + perforation. Results: Peritoneal carcinomatosis was identified during the follow-up in 19 (20 %) of patients initially diagnosed with pT4, perforated colorectal cancer or both. Conclusions: Whereas the risk of peritoneal carcinomatosis in patients with an only risk factor (pT4 or perforation) is 0-15%, it increases up to 33% (one in three patients) when both pT4 and perforation coexist. It is important to collect this information in the clinical record and considering it for the decision-making process. Second-look procedures should not be performed out of the setting of clinical trials. Some patients considered as high-risk patients in old series could have a good prognosis nowadays. [Table: see text]
- Published
- 2018
29. Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo Espanol Multidisciplinar en Cancer Digestivo (GEMCAD)
- Author
-
Aguilar, G, Albiol, S, Alcaide, J, Alonso, M, Alonso, V, Andreu, M, Aparicio, J, de la Vega, FA, Arrivi, A, Ayuso, JR, Bohn, U, Bouzas, R, Cano, JM, Castanon, C, Castells, A, Cerda, P, Cerezo, L, Conill, C, Cuatrecasas, M, del Pozo, MN, Delgado, JI, Enriquez-Navascues, JM, Escudero, P, Espin, E, Estevan, R, Falco, E, Farre, J, Feliu, J, Fernandez-Martos, C, Ferrer, AI, Gallego, R, Galvez, E, de Albeniz, XG, Olmo, DG, Garciia-Carbonero, R, Dorronsoro, MG, Martin, CG, Moreno, SG, Hernaandez, A, Iraola, A, Jimenez, E, Jimenez, MC, Jurado, I, Leno, R, Leon, A, Martin, E, Martin, M, Maurel, J, Mendez, JC, Mendez, R, Palma, P, Pardo, F, Pereira, F, Perez-Altozano, J, Perez, E, Rodriguez, J, Ruiz-Casado, AI, Sabater, L, Sarria, L, Segura, A, Sevilla, I, Tobena, M, Torres, E, Viudez, A, Zanui, M, and Zorrilla, M
- Subjects
classification ,treatment ,trial design ,colorectal cancer ,prognosis - Abstract
Advances in the care of patients with metastatic colorectal cancer arise from well-designed clinical trials. In the present document we address specific challenges in the design of clinical trials for metastatic colorectal cancer regarding staging and standard of care according to prognosis, as well as some relevant methodological issues.
- Published
- 2015
30. Noncirrhotic portal hypertension: An under-reported late adverse event of SIRT in metastatic colorectal cancer patients.
- Author
-
Gutierrez, Lourdes, Ruiz-Casado, Ana, Méndez, Santiago, Mitjavila, Mercedes, Llop, Elba, and Salas, Clara
- Subjects
- *
COLORECTAL cancer , *PORTAL hypertension , *METASTASIS , *CANCER patients , *ADVERSE health care events - Abstract
Introduction: Selective internal radiation therapy (SIRT) is increasingly used in different scenarios. Although portal hypertension (PHT) has been described as a nonclinically relevant finding after SIRT, its real incidence could have been neglected due to the nature of the diseases for which SIRT is indicated.Case Reports: Here we report three cases with clinically relevant late PHT after treatments including SIRT and oxaliplatin among others.Discussion: The sequential use of oxaliplatin and SIRT in patients with colorectal cancer metastases could have additive effects on the liver. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
31. Ideal cardiovascular health (ICVH) in patients with a recent diagnosis of colorectal cancer (CRC)
- Author
-
S. Martínez, A. Leon, Carmen Fiuza-Luces, Javier Ramos, P. Osorio, A. Sánchez, Javier Ros, Itziar Pagola, M. Mendez, Roberto E. Gómez, Ana Ruiz-Casado, A. Alvarez-Bustos, C. González, F. Hidalgo, Lidia Brea, M. A. Soriano, Lourdes Gutiérrez, Alejandro Lucia, and B. Nuñez
- Subjects
Oncology ,medicine.medical_specialty ,Colorectal cancer ,business.industry ,Internal medicine ,Cardiovascular health ,medicine ,Cancer ,In patient ,Hematology ,medicine.disease ,business - Published
- 2017
32. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy : ML18147 study KRAS subgroup findings
- Author
-
S. Kubicka, R. Greil, T. André, J. Bennouna, J. Sastre, E. Van Cutsem, R. von Moos, P. Österlund, I. Reyes-Rivera, T. Müller, M. Makrutzki, D. Arnold, J. Andel, P. Balcke, B. Benedicic, W. Eisterer, M. Fridrik, B. Jagdt, F. Keil, A. Kretschmer, P. Krippl, H. Oexle, M. Pecherstorfer, H. Samonigg, M. Schmid, J. Thaler, C. Tinchon, H. Weiss, J. Arts, M. De Man, G. Demolin, J. Janssens, M. Polus, B. Benczikova, B. Melichar, J. Prausova, P. Vitek, F.Z. Andersen, B.B. Jensen, N. Keldsen, K. Østerlind, K. Vistisen, A. Elme, A. Magi, K. Ojamaa, R. Ristamäki, T. Salminen, M. Ben Abdelghani, O. Bouche, C. Borg, K. Bouhier-Leporrier, G. Breysacher, L. Chone, M.-C. Clavero Fabri, G. Deplanque, F. Desseigne, L.-M. Dourthe, J. Ezenfis, R. Faroux, E. François, C. Garnier, M.-H. Gaspard, M. Hebbar, J.F. Illory, M.-C. Kaminsky, T. Lecomte, J.-L. Legoux, B. Levache, C. Lobry, J.-P. Lotz, M. Mabro, S. Manet-Lacombe, S. Manfredi, T. Matysiak Budnik, L. Miglianico, L. Mineur, I. Moullet, H. Naman, P. Nouyrigat, S. Oziel-Taieb, H. Perrier, D. Pezet, J. Philip, V. Pottier, M. Porneuf, M. Ramdani, D. Re, Y. Rinaldi, D. Spaeth, J. Taieb, E. Terrebonne, P. Texereau, A. Thirot Bidault, C. Tournigand, N. Tubiana-Mathieu, J.-M. Vantelon, F. Viret, M. Ychou, M. Bangerter, M.E. Bertram, B. Bohnsteen, L. Brinkmann, K. Caca, C. Constantin, H.-J. Cordes, G. Dietrich, J. Eggert, E. Engel, J. Fahlke, H. Fensterer, A. Florschütz, G. Folprecht, H. Forstbauer, W. Freier, M. Freund, N. Frickhofen, E. Gäbele, M. Geißler, F. Gieseler, T. Göhler, U. Graeven, M. Groschek, M. Grundeis, U. Hacker, V. Hagen, H.F. Hebart, S. Hegewisch-Becker, M. Heike, T. Herrmann, B. Hildebrandt, H.-G. Höffkes, G. Hübner, J. Hübner, E. Kettner, M. Kneba, J.W. Kohnke, G. Kojouharoff, C. König, A. Kretzschmar, H. Kröning, K. Kürner, F. Lammert, C. Lerchenmüller, A. Lück, J. Meiler, H.-G. Mergenthaler, L. Müller, C. Müller-Naendrup, A. Nusch, J. Papke, R. Porschen, J. Rädle, C. Reddemann, K. Ridwelski, J. Riera-Knorrenschild, J. Rudi, A. Schmalenberger, C.-C. Schimanski, F. Schlegel, C. Schlichting, P. Schmidt, W. Schmiegel, S. Schmitz, H. Schulze-Bergkamen, I. Schwaner, A. Schwarzer, M. Schwerdtfeger, J. Selbach, M. Sieber, J. Siebler, P. Staib, M. Stauch, C.-C. Steffens, P. Stübs, J. Tischendorf, T. Trarbach, D. Tummes, A.-R. Valdix, A. Vogel, G.P.L. Von Wichert, M. Walther, W. Welslau, G. Wilhelm, H. Wobster, T. Wolf, N. Zeigenhagen, B. Zomorodbaksch, E. Batman, H.J. Bloemendal, D.F.S. Kehrer, T. Guren, G. Indrebø, C. Kersten, H. Soerbye, M. Fragoso, R. Fragoso, J.C. Mellidez, A. Sa, A. Aljobran, T. Darwish, V. Alonso-Orduna, J. Aparicio, E. Aranda, C. Bosch, A. Galan-Brotons, I. Busquier Hernandez, J.C. Camara, J.M. Campos Cervera, C. Carlos Garcia Giron, P.M. Del Prado, O. Donnay, P. Escudero, E. Falco, J. Gallego Plazas, P. Garcia Alfonso, E. Gonzalez Flores, C. Gravalos, R. Guardeno, A. Juárez, A. Lopez Ladron, F. Losa Gaspa, J. MªVicent Vergé, E. Marcuello Gaspar, B. Massuti Sureda, J. Molina, I.C. Montero, A.L. Muñoa, M.B. Naranjo, M.J. Oruezabal Moreno, V. Pachón Olmos, C. Pericay, J.J. Reina Zoilo, F. Rivera, A. Ruiz Casado, M.J. Safont, A. Salud Salvia, M. Tobena, J.C. Toral, V. Valenti, M. Valladares Ayerbes, J.M. Vieitez, R. Vera, A. Berglund, E. Fernebro, V. Hess-Umbricht, M. Pless, R. Popescu, R. Winterhalder, and Trarbach, Tanja (Beitragende*r)
- Subjects
Adult ,Male ,Vascular Endothelial Growth Factor A ,Oncology ,medicine.medical_specialty ,Survival ,Bevacizumab ,Colorectal cancer ,medicine.medical_treatment ,Medizin ,Antibodies, Monoclonal, Humanized ,medicine.disease_cause ,Disease-Free Survival ,Proto-Oncogene Proteins p21(ras) ,Capecitabine ,Young Adult ,Proto-Oncogene Proteins ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,medicine ,Humans ,Prospective Studies ,Neoplasm Metastasis ,neoplasms ,Aged ,Aged, 80 and over ,Chemotherapy ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,Chemotherapy regimen ,digestive system diseases ,Oxaliplatin ,Surgery ,Treatment Outcome ,Fluorouracil ,ras Proteins ,Female ,KRAS ,Colorectal Neoplasms ,business ,medicine.drug - Abstract
ML18147 evaluated continued bevacizumab with second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) progressing after the standard first-line bevacizumab-containing therapy.Evaluating outcomes according to tumor Kirsten rat sarcoma virus oncogene (KRAS) status was an exploratory analysis. KRAS data were collected from local laboratories (using their established methods) and/or from a central laboratory (mutation-specific Scorpion amplification-refractory mutation system). No adjustment was made for multiplicity; analyses were not powered to detect statistically significant differences.Of 820 patients, 616 (75%) had unambiguous KRAS data; 316 (51%) had KRAS wild-type tumors and 300 (49%) had mutant KRAS tumors. The median progression-free survival (PFS) was 6.4 months for bevacizumab plus chemotherapy and 4.5 months for chemotherapy [P0.0001; HR = 0.61; 95% confidence interval (CI): 0.49-0.77] for wild-type KRAS and 5.5 and 4.1 months, respectively (P = 0.0027; HR = 0.70; 95% CI: 0.56-0.89) for mutant KRAS. The median overall survival (OS) was 15.4 and 11.1 months, respectively (P = 0.0052; HR = 0.69; 95% CI: 0.53-0.90) for wild-type KRAS and 10.4 versus 10.0 months, respectively (P = 0.4969; HR = 0.92; 95% CI: 0.71-1.18) for mutant KRAS. In both analyses, no treatment interaction by KRAS status was observed (PFS, P = 0.4436; OS, P = 0.1266).Bevacizumab beyond first progression represents an option for patients with mCRC treated with bevacizumab plus standard first-line chemotherapy, independent of KRAS status.
- Published
- 2013
33. Liver metastases of colon cancer: New therapeutic approaches. Neoadjuvant chemotherapy
- Author
-
Ana Ruiz-Casado and F. Pereira
- Subjects
Oncology ,Isolated liver ,medicine.medical_specialty ,Chemotherapy ,Colorectal cancer ,business.industry ,Surrogate endpoint ,medicine.medical_treatment ,Disease ,medicine.disease ,Neoadjuvant chemotherapy ,Colon cancer ,Clinical trial ,Liver metastases ,Internal medicine ,medicine ,business ,Median survival ,Neoadjuvant therapy - Abstract
Colon cancer witnesses one of most exciting and evolving times in the latest years. About 30% of patients with isolated liver colon- metastases can now be cured through a multidisciplinary approach of the disease. New systemic treatments have moved the median survival of metastatic disease from 12 months four years ago to 20 months and beyond. Incorporation of new biologic treatments into the neoadjuvant setting may help to further improve historical outcomes and offers promise to continue this trend. Appropriate surrogate endpoints and optimal designs of clinical trials on neoadjuvant therapy as first or second-line of treatment are needed.
- Published
- 2006
34. 4252 POSTER Multidisciplinary Recommendation of Physical Activity for Patients With Rectal Cancer During Neoadjuvant Therapy
- Author
-
J. Martin Moreno, J.A. Guerra Martinez, M.R. Lopez Melero, J.J. Garcia Arroyo, M.J. Ortega Solano, L. Brea Alejo, A. Ruiz Casado, D. Gonzalez Bravo, A. Soria Verduqo, and M.E. Garcia Vega
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,medicine.medical_treatment ,Physical activity ,Cancer ,medicine.disease ,Multidisciplinary approach ,Internal medicine ,medicine ,business ,Neoadjuvant therapy - Published
- 2011
35. 1564P Cancer-related fatigue in colorectal cancer patients at the time of diagnosis.
- Author
-
Ruiz-Casado, A., Franco, F.F., Romero-Elias, M., Fiuxa, C., Gutiérrez Sanz, L., Alvarez-Bustos, A., Sanchez Ruiz, A., Garcia Gonzalez, D., Gonzalez-Cutre, D., and Cebolla, H.
- Subjects
- *
COLORECTAL cancer , *CANCER patients , *CANCER fatigue , *DIAGNOSIS - Published
- 2022
- Full Text
- View/download PDF
36. 600TiP A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC).
- Author
-
Elez Fernandez, M.E., Rosello Keranen, S., Paez, D., Jiménez Castro, J., Rivera Herrero, F., Ruiz-Casado, A., Riesco Martinez, M.C., Montagut Viladot, C., Coupez, D., Ducreux, M.P., Loly, C., Martin-Babau, J., Prenen, H., van den Eynde, M., Borg, C., Cuyle, P-J., de Haar-Holleman, A., Raimbourg, J., Bechar, N., and Tabernero, J.
- Subjects
- *
COLORECTAL cancer , *METASTASIS , *CANCER chemotherapy , *BEVACIZUMAB , *PLACEBOS - Published
- 2024
- Full Text
- View/download PDF
37. 1832P Physical condition is associated with quality of life in colorectal cancer survivors: Results from a Portuguese and Spanish cohort of patients.
- Author
-
Soares Miranda, L.M.D.C., Romero-Elias, M., Silva, M., Peixoto, A., Mota, J., Macedo, G., Abreu, S., and Ruiz-Casado, A.
- Subjects
- *
COLORECTAL cancer , *CANCER survivors , *PHYSICAL training & conditioning , *QUALITY of life - Published
- 2024
- Full Text
- View/download PDF
38. 604P Overall and progression-free survival of patients with metastatic colorectal cancer: A real-world prospective, longitudinal cohort study on the continuum of care (PROMETCO).
- Author
-
Koopman, M., Garcia-Carbonero, R., Pinto, C., Mitroshkin, A., Bodoky, G., Mineur, L., Bourgeois, V., Mare, M., Ruiz-Casado, A., Fernandez Montes, A., O'Connor, J.M.R., Sullivan, A., Choucair, E., Sicaire, M., Marti, F.E., and Bachet, J-B.
- Subjects
- *
OVERALL survival , *CONTINUUM of care , *PROGRESSION-free survival , *COLORECTAL cancer , *METASTASIS - Published
- 2023
- Full Text
- View/download PDF
39. 605P First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort.
- Author
-
Oliveres, H., Alonso-Orduna, V., Feliu, J., Fernandez Montes, A., Martin-Richard, M., Galvez Munoz, E., Ruiz-Casado, A., Yubero Esteban, A., Aparicio, J., Alcaide-Garcia, J., Gallego Plazas, J., Carmona-Bayonas, A., Fernandez Martos, C., Gallego, M.R., Manzano Alemany, H., Leno, R., Esposito, F.M., Sapena, V., and Maurel, J.
- Subjects
- *
COLORECTAL cancer , *METASTASIS , *CANCER chemotherapy - Published
- 2023
- Full Text
- View/download PDF
40. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.
- Author
-
Toledano-Fonseca, M., Gómez-España, M.A., Élez, E., Grávalos, C., García-Alfonso, P., Rodríguez, R., Losa, F., Alés Díaz, I., Graña, B., Valladares-Ayerbes, M., García-Ortiz, M.V., Polo, E., Salgado, M., Rivera, F., Safont, M.J., Salud, A., Ruiz-Casado, A., Tabernero, J.M., Riesco, M.C., and Rodríguez-Ariza, A.
- Subjects
- *
COLORECTAL cancer , *CANCER chemotherapy , *AFLIBERCEPT , *METASTASIS , *CANCER patients - Abstract
The benefit of adding the antiangiogenic drug aflibercept to FOLFIRI regime in metastatic colorectal cancer (CRC) patients resistant to or progressive on an oxaliplatin-based therapy has been previously demonstrated. However, the absence of validated biomarkers to predict greater outcomes is a major challenge encountered when using antiangiogenic therapies. In this study we investigated profiles of circulating microRNAs (miRNAs) to build predictive models of response to treatment and survival. Plasma was obtained from 98 metastatic CRC patients enrolled in a clinical phase II trial before receiving FOLFIRI plus aflibercept treatment, and the circulating levels of 754 individual miRNAs were quantified using real-time PCR. A distinct signature of circulating miRNAs differentiated responder from non-responder patients. Remarkably, most of these miRNAs were found to target genes that are involved in angiogenic processes. Accordingly, some of these miRNAs had predictive value and entered in predictive models of response to therapy, progression of disease, and survival of patients treated with FOLFIRI plus aflibercept. Among these miRNAs, circulating levels of hsa-miR-33b-5p efficiently discriminated between responder and non-responder patients and predicted the risk of disease progression. Moreover, the combination of circulating VEGF-A and miR-33b-5p levels improved clinical stratification of metastatic CRC patients who were to receive FOLFIRI plus aflibercept treatment. In conclusion, our study supports circulating miRNAs as valuable biomarkers for predicting better outcomes in metastatic CRC patients treated with FOLFIRI plus aflibercept. [Display omitted] • Predict response to treatment is a challenge when using antiangiogenic therapies. • Aflibercept is an antiangiogenic VEGF-targeted agent for colorectal cancer. • Circulating miRNAs discerned responder from non-responder patients. • Combining VEGF-A and miR-33b-5p improves patient selection for aflibercept therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. 1568P Physical condition in patients with a recent diagnosis of colorectal cancer.
- Author
-
Romero-Elias, M., Alvarez-Bustos, A., Garcia Gonzalez, D., Franco, F.F., Aguado, R., Gutierrez Sanz, L., Sanchez Ruiz, A., Cebolla, H., Gonzalez-Cutre, D., and Ruiz-Casado, A.
- Subjects
- *
COLORECTAL cancer , *CANCER diagnosis , *PHYSICAL training & conditioning - Published
- 2022
- Full Text
- View/download PDF
42. 342P A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.
- Author
-
Rodriguez-Ariza, A., Gomez España, M.A., Elez Fernandez, M.E., Gravalos Castro, M.C., García Alfonso, P., Losa, F., Ales Diaz, I.C., Grana Suarez, B., Gallego, I., García-Ortiz, M.V., Polo Marques, E., Salgado Fernandez, M., Rivera Herrero, F., Safont Aguileria, M.J., Salud Salvia, M.A., Ruiz-Casado, A., Tabernero, J., Riesco Martinez, M.C., Toledano-Fonseca, M., and Ara Aguilar, E.
- Subjects
- *
COLORECTAL cancer , *METASTASIS , *CANCER patients , *CANCER chemotherapy , *AFLIBERCEPT - Published
- 2022
- Full Text
- View/download PDF
43. 474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC).
- Author
-
Gomez, O. Higuera, Soto, V. Heredia, Machado, I., Mendez, M.C., Cuatrecasas, M., Horndler, C., Vermeulen, L., Hoorn, S. Ten, Mendiola, M., Martín-Richard, M., Ruiz-Casado, A., Galvez, E., Aparicio, J., García, I. Sevilla, Leno, R., Fernández-Martos, C., Alonso-Orduna, V., Montes, A. Fernandez, Maurel, J., and Feliu, J.
- Subjects
- *
COLORECTAL cancer , *METASTASIS , *IMMUNOHISTOCHEMISTRY , *CANCER - Published
- 2020
- Full Text
- View/download PDF
44. O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer.
- Author
-
Van Cutsem, E., Taieb, J., Yaeger, R., Yoshino, T., Maiello, E., Elez, E., Dekervel, J., Ross, P., Ruiz Casado, A., Graham, J., Kato, T., Ruffinelli, J., André, T., Carriere Roussel, E., Klauck, I., Groc, M., Grothey, A., Vedovato, J., and Tabernero, J.
- Subjects
- *
CETUXIMAB , *BRAF genes , *COLORECTAL cancer - Published
- 2021
- Full Text
- View/download PDF
45. 471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score.
- Author
-
Seguí, E., Alonso-Orduna, V., Sesma, A., Martin-Richard, M., Salud, A., Fernández-Montes, A., Fernández-Martos, C., Ruiz-Casado, A., Gallego, J., Aparicio, J., Gálvez, E., Manzano, H., Alcaide-Garcia, J., Gallego, R., Falco, E., Esposito, F., Oliveres, H., Torres, F., Feliu, J., and Maurel, J.
- Subjects
- *
COLORECTAL cancer , *METASTASIS - Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.